This Article Full Text Full Text (PDF) All Versions of this Article: 200505-840OEv1 173/5/475    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, P. B. Search for Related Content PubMed PubMed Citation Articles by Davis, P. B.

Cystic Fibrosis Since 1938

Department of Pediatrics, Case Western Reserve University School of Medicine at Rainbow Babies' and Children's Hospital, Cleveland, Ohio

Correspondence and requests for reprints should be addressed to Pamela B. Davis, M.D., Ph.D., Department of Pediatrics, Case Western Reserve University School of Medicine at Rainbow Babies' and Children's Hospital, BRB 8th floor, 2109 Adelbert Road, Cleveland OH 44106. E-mail: pamela.davis{at}case.edu

ABSTRACT

Cystic fibrosis (CF) was distinguished from celiac disease in 1938. Then, it was a pathologic diagnosis, life expectancy was approximately 6 months, and the autosomal recessive disease was believed to arise from abnormal mucus plugging exocrine ducts. Death often occurred from lung infection. Discovery of the sweat electrolyte defect in 1953 and standardization of the sweat test in 1959 allowed identification of milder cases, and CF was no longer considered only a disorder of mucus. In 1955, establishment of centers with programs of aggressive, comprehensive care initiated striking improvement in longevity. The pillars of care established then (attention to nutrition, airway clearance, treatment of lung infection) remain today. In 1983, chloride transport was identified as the basic physiologic CF defect, accompanied by increased sodium reabsorption. In 1980, we learned that inflammation contributes independently to lung disease and constitutes an independent therapeutic target. In 1989, the discovery of the CF gene demonstrated the basic defect to be in a cAMP-regulated chloride channel. This afforded new diagnostic tests, opportunities for research, and prospects for using the gene as therapy. Since then, substantial advances in basic and clinical research catalyzed therapeutic improvements: median survival age now exceeds 30 years. The Cystic Fibrosis Foundation center network provides not only opportunity to conduct clinical trials but also means to disseminate new therapies. In the future, treatments directed at the basic defect can be expected, with concomitant improvements in morbidity and mortality.

Key Words: cystic fibrosis • Pseudomonas aeruginosa • sweat test

This article has been cited by other articles:

				B. Lubamba, J. Lebacq, P. Lebecque, R. Vanbever, A. Leonard, P. Wallemacq, and T. Leal Airway Delivery of Low-Dose Miglustat Normalizes Nasal Potential Difference in F508del Cystic Fibrosis Mice Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 1022 - 1028. [Abstract] [Full Text] [PDF]

				M. Makam, D. Diaz, J. Laval, Y. Gernez, C. K. Conrad, C. E. Dunn, Z. A. Davies, R. B. Moss, L. A. Herzenberg, L. A. Herzenberg, et al. Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs PNAS, April 7, 2009; 106(14): 5779 - 5783. [Abstract] [Full Text] [PDF]

				L. K. Moores Unusual Lung Infection, Bronchiectasis, and Cystic Fibrosis ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 1 - 20. [Full Text] [PDF]

				A. von Drygalski and J. Biller Anemia in Cystic Fibrosis: Incidence, Mechanisms, and Association With Pulmonary Function and Vitamin Deficiency Nutr Clin Pract, October 1, 2008; 23(5): 557 - 563. [Abstract] [Full Text] [PDF]

				I Kukavica-Ibrulj and R C Levesque Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies Lab Anim, October 1, 2008; 42(4): 389 - 412. [Abstract] [Full Text] [PDF]

				U. Griesenbach, S. N. Smith, R. Farley, C. Singh, and E. W. F. W. Alton Validation of Nasal Potential Difference Measurements in Gut-Corrected CF Knockout Mice Am. J. Respir. Cell Mol. Biol., October 1, 2008; 39(4): 490 - 496. [Abstract] [Full Text] [PDF]

				T. M. Kremer, R. G. Zwerdling, P. H. Michelson, and B. P. O'Sullivan Intensive Care Management of the Patient With Cystic Fibrosis J Intensive Care Med, May 1, 2008; 23(3): 159 - 177. [Abstract] [PDF]

				R. Tirouvanziam, Y. Gernez, C. K. Conrad, R. B. Moss, I. Schrijver, C. E. Dunn, Z. A. Davies, L. A. Herzenberg, and L. A. Herzenberg Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways PNAS, March 18, 2008; 105(11): 4335 - 4339. [Abstract] [Full Text] [PDF]

				A. W. R. Serohijos, T. Hegedus, A. A. Aleksandrov, L. He, L. Cui, N. V. Dokholyan, and J. R. Riordan Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function PNAS, March 4, 2008; 105(9): 3256 - 3261. [Abstract] [Full Text] [PDF]

				J. C Davies, E. W F W Alton, and A. Bush Cystic fibrosis BMJ, December 15, 2007; 335(7632): 1255 - 1259. [Full Text] [PDF]

				J. Donadieu, C. Roudier, M. Saguintaah, C. Maccia, and R. Chiron Estimation of the Radiation Dose From Thoracic CT Scans in a Cystic Fibrosis Population Chest, October 1, 2007; 132(4): 1233 - 1238. [Abstract] [Full Text] [PDF]

				S. M. Rowe, F. Accurso, and J. P. Clancy Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials Proceedings of the ATS, August 1, 2007; 4(4): 387 - 398. [Abstract] [Full Text] [PDF]

				P. M. Quinton Cystic Fibrosis: Lessons from the Sweat Gland Physiology, June 1, 2007; 22(3): 212 - 225. [Abstract] [Full Text] [PDF]

				F. J. Accurso Update in Cystic Fibrosis 2006 Am. J. Respir. Crit. Care Med., April 15, 2007; 175(8): 754 - 757. [Full Text] [PDF]

				I. D. Wexler, M. Johannesson, F. P. Edenborough, B. S. Sufian, and E. Kerem Pregnancy and Chronic Progressive Pulmonary Disease Am. J. Respir. Crit. Care Med., February 15, 2007; 175(4): 300 - 305. [Abstract] [Full Text] [PDF]

				A. Livraghi and S. H. Randell Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance Toxicol Pathol, January 1, 2007; 35(1): 116 - 129. [Abstract] [Full Text] [PDF]

				A. Roghanian, E. M. Drost, W. MacNee, S. E. M. Howie, and J.-M. Sallenave Inflammatory Lung Secretions Inhibit Dendritic Cell Maturation and Function via Neutrophil Elastase Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1189 - 1198. [Abstract] [Full Text] [PDF]

				D. Gayer and L. Ganong Family Structure and Mothers' Caregiving of Children With Cystic Fibrosis Journal of Family Nursing, November 1, 2006; 12(4): 390 - 412. [Abstract] [PDF]

				N N Sanders, H Franckx, K De Boeck, J Haustraete, S C De Smedt, and J Demeester Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax, November 1, 2006; 61(11): 962 - 966. [Abstract] [Full Text] [PDF]